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Summary
Atrial fibrillation (AF) is the most common atrial ar-
rhythmia, with a prevalence of 1–2% in the general pop-
ulation. It increases with age, affecting approximately 7%
of individuals age >65 years and 15–20% of octogenarians.
The human left atrium has a blind sac-like remnant, called
left atrial appendage (LAA). It originates from a primordial
pulmonary vein. Due to its complicated structure, blind
end and inner surface trabeculated by pectinate muscles,
thrombi in nonvalvular AF form almost exclusively in the
LAA and not in the smooth-walled left atrium. For the last
50 years, oral anticoagulation (OAC) with vitamin K ant-
agonists (VKAs) has been the only treatment option to pre-
vent stroke and systemic embolism from thrombi in AF.
More recently, non-vitamin K-dependant oral anticoagu-
lants (NOACs) have been shown to be noninferior or even
superior to VKA with respect to efficacy and safety. In light
of the limitations of indefinite OAC, particularly among
patients at increased risk for bleeding and because thrombi
arise predominantly from the LAA among AF patients, ex-
clusion of the LAA with closure devices (LAAC) provides
a novel treatment strategy for prevention of stroke and
bleeding. Recently, LAAC has been compared with VKA
therapy in prospective randomised trials with promising
results. Today, the decision to provide the most appropriate
treatment for a patient with AF (OAC, NOAC or LAAC)
is complex and needs to be individualised. This review
provides an update on the current state of LAAC in the
field of stroke prevention in patients suffering from non-
Abbreviations
AF atrial fibrillation
CT computed tomography
FDA Food and Drug Administration of the United States of America
INR international normalised ratio
LAA left atrial appendage
LAAC left atrial appendage closure
NOAC non-vitamin K-dependent oral anticoagulant
OAC oral anticoagulation
PFO patent foramen ovale
RRR relative risk reduction
TIA transient ischaemic attack
TOE transoesophageal echocardiography
VKA vitamin K antagonist
valvular AF. We describe the pathophysiology of the LAA
with regard to stroke. Aside from the evidence and limita-
tions of anticoagulation as the classical treatment paradigm
for stroke prevention, devices and techniques for LAAC
are outlined and the current clinical evidence with regard to
efficacy and safety is reviewed. Finally, contemporary re-
commendations for patient selection are provided.
Key words: anticoagulation; atrial fibrillation; left atrial
appendage closure; stroke; bleeding
Introduction
Atrial fibrillation (AF) is the most common atrial ar-
rhythmia, with a prevalence of 1–2% in the general popula-
tion that increases with age to affect approximately 7% of
individuals aged >65 years and 15–20% of octogenarians
[1–3]. Patients with AF are at increased risk of thromboem-
bolism, in particular ischaemic stroke. It is estimated that
every fifth stroke is related to AF [3]. Strokes related to AF
tend to be especially severe and disabling, and half of the
patients die within 1 year of the event. Patients with AF are
also at increased risk of death (two-fold) and heart failure
(three-fold), and AF is responsible for 3–6% of acute med-
ical admissions for management of arrhythmia [4]. Of note,
AF frequently goes undetected and therefore not all affec-
ted patients receive appropriate treatment [5].
For estimation of individual stroke risk, the comorbidities
of any patient suffering from AF have to be taken into con-
sideration. Current guidelines recommend the use of the
CHA2DS2-VASc score, which provides an estimate of the
annual stroke risk with the advice to implement oral anti-
coagulation (OAC) for prevention of thromboembolism in
the case of CHA2DS2-VASc scores ≥1 [4, 6].
Structure and function of the left
atrial appendage
The left atrial appendage (LAA) is a remnant of a prim-
ordial pulmonary vein and is located anteriorly in the at-
rioventricular groove in close proximity to the left cir-
cumflex coronary artery, the annulus of the mitral valve,
the left upper pulmonary vein and the left phrenic nerve.
Owing to the small volume and in spite of the contractility
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 1 of 15
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
89
72
7 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7
of the LAA during normal sinus rhythm, it plays only a
minor role in the regulation of pressure, volume and left
ventricular filling [7]. With volumes of 5–15 ml, the LAA
is markedly smaller than the right atrial appendage and its
inner surface is trabeculated by pectinate muscles [8, 9].
Although the shape of the LAA is highly variable, it usu-
ally resembles a rather narrow tube with numerous bends.
Four principal morphologies have been described: cactus,
chicken wing, windsock and cauliflower appearances. It
has also been suggested that LAA morphology is directly
linked to the risk of stroke [10, 11], where patients with
LAA morphology other than chicken wing appear at high-
er risk for thromboembolic events after controlling for co-
morbidities and CHADS2 score [12].
Remodelling of the left atrial
appendage and pathophysiology in
atrial fibrillation
AF results in loss of physiological atrial systole and ir-
regular ventricular activation, which in turn affects left
ventricular filling and contractility, and cardiac output. As
a result, left atrial pressures and volumes are typically in-
creased due to stasis. Depending on the frequency and dur-
ation of AF, as well as left ventricular systolic and diastol-
ic function and afterload, both the left atrium and the LAA
undergo a progressive process of remodelling with subse-
quent enlargement and reduced blood flow velocities in-
cluding turbulent flow and stasis [9, 13–15].
The LAA has been known as a potential nidus of thrombus
formation and location for more than 60 years and the first
surgical resection of the LAA was published in 1949 [16].
A recent meta-analysis of >20000 AF patients with non-
valvular AF reported a mean prevalence for any left atrial
thrombi of 10%, which was linked to a 3.5-fold increase in
stroke risk [17]. Evidence from echocardiographic, surgic-
al and postmortem studies revealed that the vast majority
of intracardiac thrombi in patients with nonvalvular AF are
located in the LAA. In a large study using transoesopha-
geal echocardiography (TOE), 91% of thrombi were loc-
ated in the LAA [18]. Of note, thrombi can be detected
within a relatively short period of time in the LAA in up
to 14% of patients with acute or new onset (<3 days) AF
[19]. In valvular AF, which comprises patients with rheum-
atic mitral stenosis or metallic valve prostheses, left atrial
flow is even more reduced and therefore the prevalence of
left atrial thrombi is as high as 45% [20]. At variance with
nonvalvular AF and owing to the even more thrombogen-
etic milieu in the presence of mitral stenosis or a mechan-
ical prosthesis, thrombi originate more frequently from the
left atrium: in a clinicopathological study, about half of the
left-sided thrombi were observed in the LAA, whereas the
remainder were located at the free walls of the left atrium
[21].
Oral anticoagulation for stroke
prevention
Oral anticoagulation (OAC) with vitamin K antagonists
(VKAs) or, more recently, non-vitamin K-dependent oral
anticoagulants (NOACs) is the mainstay of the prevention
of thromboembolism among patients with AF. OAC with a
VKA as compared with placebo is associated with an ab-
solute stroke risk reduction of 2.7% per year, which cor-
responds to a relative risk reduction of 64% and a number
needed to treat of 37 per year [22]. Although antiplatelet
therapy with acetylsalicylic acid alone or dual antiplatelet
therapy consisting of acetylsalicylic acid and clopidogrel
lowers the risk of stroke as compared with placebo by ap-
proximately 20%, OAC with a VKA is substantially more
effective than antiplatelet therapy by approximately 40%.
More recently, NOACs have been introduced into clinical
practice. They have several advantages over VKAs includ-
ing rapid onset (2–4 hours), rapid offset (24 hours) and pre-
dictable pharmacokinetic effects, combined with a favour-
able safety and efficacy profile. A prespecified, pooled ana-
lysis of four randomised clinical trials (RELY, ROCKET
AF, ARISTOTLE, ENGAGE AF-TIMI) included 71683
patients with AF and compared clinical outcomes of dif-
ferent NOACs with VKAs. The results showed a 19%
lower risk of stroke and systemic embolism (relative risk
[RR] 0.81, 95% confidence interval [CI] 0.73–0.91), a 50%
lower risk of haemorrhagic stroke (RR 0.49, 95% CI
0.49–061, p <0.0001), and a 10% lower risk of mortality
(RR 0.90, 95% CI 0.85–0.95, p = 0.0003) in favour of
NOACs [23]. Of note, major bleeding tended to be lower
with NOACs than VKAs (RR 0.86, 95% CI 0.73–1.00,
p = 0.06). AVERROES compared the NOAC apixaban
with acetylsalicylic acid in patients with AF who had an
absolute or relative contraindication for a VKA. In this
study, the treatment with apixaban as compared with acet-
ylsalicylic acid improved efficacy in terms of reducing the
risk of stroke and systemic embolism (hazard ratio [HR]
0.45, 95% CI 0.32–0.62, p <0.01) while providing a sim-
ilar safety profile (HR = 1.13, 95% CI 0.74–1.75, p =
0.57) [24]. In view of the robust evidence in favour of
OAC in patients with AF, current guidelines recommend
the initiation of an (N)OAC in patients with CHA2DS2-
VASC score of 1 (class IIa A) and CHA2DS2-VASC score
≥2 (class I A) after weighing the bleeding risk using the
HASBLED score. These guidelines also give preference
to NOACs over VKAs (Class IIa A) for most AF patients
based on the net clinical benefit outlined above, with the
exception of patients with valvular AF, for whom OAC
with a VKA is still recommended as the preferred treatment
[4].
Shortcomings of oral anticoagulation
OAC is highly effective but is not free of limitations. As
it relates to VKAs, a large US study has recently shown
that only about half (54%) of patients are adequately pro-
tected as maintenance of a therapeutic prothrombin time in-
ternational normalised ratio (INR) remains infrequent [25].
Moreover, approximately one third of patients with AF do
not receive OAC or discontinue therapy once started for a
variety of reasons, and therefore have no protection against
thromboembolism [26, 27]. Thus, the rate of premature and
permanent discontinuation amounted to 55% in patients
treated with warfarin [28] and 34% in patients who had re-
ceived edoxaban [29] within 2–3 years after initiation of
treatment in well supervised, controlled clinical trials. Ac-
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cordingly, a substantial proportion of patients who have an
indication for OAC remain untreated and have no sufficient
stroke prophylaxis.
Bleeding complications are more common with therapeutic
OAC. The assessment of individual bleeding risk according
to scores such as the HAS-BLED (hypertension, abnormal
liver function, abnormal renal function, stroke, bleeding,
labile INR, elderly, drugs, or alcohol) score [30] or ATRIA
score [31] should be part of any risk/benefit evaluation for
optimal treatment of patients with AF. HAS-BLED scores
in excess of 3 are associated with a high bleeding risk, i.e.,
an incidence of major bleedings of 5.8% per 100 patient-
years [4]. Recent data from randomised trials comparing a
NOAC with warfarin indicate major bleeding event rates in
the range of 1.9% to 3.6% per year for NOACs and 3.1% to
4.2% per year for warfarin [29, 32–34]. Although NOACs
have substantially reduced the risk of intracranial haem-
orrhage as compared with VKAs, the risk of gastrointest-
inal bleeding is similar or higher. It also has to be taken
into consideration that patients with the highest CHA2DS2-
VASC score frequently have the highest HAS-BLED score.
Particularly, the growing population of very elderly pa-
tients is at increased bleeding risk or has already experien-
ced either spontaneous bleeding or bleeding under OAC.
Finally, specific patient populations such as those with
severe, chronic renal failure are at increased risk of bleed-
ing, have not been studied in randomised trials and repres-
ent a relative contraindication for NOAC therapy.
Rationale for left atrial appendage
closure
Owing to the intrinsic limitations of oral anticoagulation
and the anatomical and pathophysiological features of the
LAA in patients with AF, an alternative concept for throm-
boembolic protection has been developed: the surgical ex-
clusion or percutaneous closure of the LAA (LAAC). It
was first performed surgically in the late 1940s. In this mil-
lennium, effective LAAC has been introduced by means of
a nonsurgical, minimally invasive catheter-based interven-
tion [35, 36].
Surgical exclusion of the left atrial
appendage
The initial version of the cut and sew Cox-Maze procedure
for treatment of AF included the excision or closure of the
LAA [37] (fig. 1, panel A). In a large study (>400 patients)
by Johnson and colleagues, prophylactic LAA removal was
reported to be feasible and safe. It was advocated that it
should be considered as an additional therapy to any heart
surgery [38]. A retrospective study, investigating the addi-
tion of surgical LAA removal among patients undergoing
mitral valve replacement in a high-risk population, repor-
ted a reduction of the risk of stroke and systemic embolism
[39]. A recent large, observational study in 1831 patients
has shown that additional surgical LAA removal during
cardiac surgery in patients at low stroke risk reduced the in-
cidence of postoperative cerebrovascular accidents [40].
Currently, the large-scale (4700 patients) Left Atrial Ap-
pendage Occlusion Study (LAAOS) III is comparing con-
comitant surgical LAAC with no LAA closure in patients
with AF or atrial flutter who are undergoing routine cardiac
surgery. Of note, OAC is continued in both groups [41],
with follow-up through 4 years.
The 2014 European Society of Cardiology (ESC) /
European Association for Cardio-Thoracic Surgery
(EACTS) guidelines on myocardial revascularisation
provide guidance as to the addition of LAAC to surgical
coronary revascularisation or valvular surgery in patients
with AF with a class IIb B recommendation [42].
Apart from suture-based endocardial surgical techniques,
placement of an epicardial clip with a dedicated device
(AtriClip, Atricure Inc., Ohio, USA) has shown a high pro-
cedural success in >95% with favourable safety and per-
sistent closure (98%) at follow-up. Long-term studies to
determine the clinical efficacy are not yet available [43].
Percutaneous closure of the left atrial
appendage
The first dedicated LAAC device was implanted in humans
in 2001 (PLAATO, percutaneous left atrial appendage tran-
scatheter occlusion device, Appriva Medical Inc., Califor-
nia, USA), but is no longer commercially available [35].
Only shortly thereafter in 2002, the first LAAC was per-
formed with implantation of a nondedicated Amplatzer at-
rial septal occluder device (St. Jude Medical, Minnesota,
USA) [36]. Subsequently, the specifically designed and
dedicated Amplatzer cardiac plug (ACP) was launched and
CE-mark approved in 2008. The device, which is currently
Figure 1
Different techniques, devices, and results for left atrial appendage
closure (LAAC).
In panel A, surgical endocardial closure by exclusion with a double
layer suture is depicted. Note the proximity of the left atrial
appendage (LAA) to the left pulmonary veins (LPVs) and the mitral
valve (MV). Derived and modified from Robertson et al. [71]
(© 2016 Beth Croce).
In panels B and C, the two most common devices for percutaneous
LAAC are shown (B: derived and modified from St. Jude Medical,
Minnesota, USA; C: Image provided courtesy of Boston Scientific.
© 2016 Boston Scientific Corporation or its affiliates. All rights
reserved). In contrast to the Watchman, a membrane-cap device
(C), the Amplatzer systems are plug-and-disc (pacifier) devices
Panel D depicts another membrane-cap device, the Coherex
Wavecrest (derived and modified from Coherex Medical, Utah,
USA). In panels E and F, the Amplatzer and Watchman devices are
shown after endocardialisation in anatomical preparations of canine
models (derived and modified from Kar et al. [72] Impact of
Watchman and Amplatzer devices on left atrial appendage adjacent
structures and healing response in a canine model. JACC
Cardiovasc Interv. 2014;7(7):801–9, with permission from Elsevier).
Review article: Biomedical intelligence Swiss Med Wkly. 2016;146:w14298
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 3 of 15
in its second generation (Amulet) consists of a distal body
with small stabilisation wires that results in obliteration of
the LAA cavity and anchors the device, as well as a prox-
imal disc to enable coverage, i.e., exclusion of the LAA os-
tium according to the pacifier principle. The device is man-
ufactured from a self-expanding nitinol mesh (fig. 1, panels
B and E).
The Watchman LAAC device (Boston Scientific, Mas-
sachussets, USA, CE approved in 2005 and approved by
the US Food and Drug Administration [FDA] in 2015)
was implanted for the first time in the year 2002, a few
months after the Amplatzer device, and since then has un-
dergone further refinement [44]. Unlike the plug-and-disc
(pacifier) concept of the Amplatzer systems, the Watchman
is a membrane-cap plug system (fig. 1, panel C and F). It
is made of a self-expanding nitinol frame with ten fixation
anchors and a cover of permeable polyethylene terephthal-
ate.
The Coherex Wavecrest occluder (Coherex Medical, Utah,
USA) is the third catheter-based device, which also comes
with a membrane-cap plug design. It received CE approval
in 2013 (fig. 1, panel D). As yet, no clinical data with
meaningful follow-up have been published.
Several additional interventional devices are in the stage
of clinical or preclinical evaluation. The catheter-based
LARIAT (SentreHEART Inc., California, USA) device
uses a hybrid endocardial and epicardial approach, is ap-
proved by FDA and has obtained the CE mark. The Am-
platzer ACP/Amulet and the Watchman are the devices
with which there is most clinical experience reported to
date.
The wide variability of LAA morphology requires careful
preprocedural planning in order to determine the most ad-
equate device [45]. Prior to the procedure, most patients
undergo TOE to rule out any thrombi in the LAA and to
determine anatomical specifications and size. Computed
tomography (CT) of the heart with three-dimensional re-
construction of the LAA also provides high spatial and
temporal resolution allowing for detailed description of the
anatomy. It plays an increasing role in device selection and
intervention planning [45–47]. On the other hand, ad hoc
LAAC with invasive angiography and fluorocsopic guid-
ance only, with no prior imaging of any kind, has been suc-
cessfully performed [48]. Following percutaneous puncture
of the femoral vein, left atrial access is usually gained via
transseptal puncture or, less frequently, by passage through
a patent foramen ovale (PFO) or an atrial septal defect
[49]. Thereafter, a device-specific sheath is advanced over
a guidewire into the left atrium and directed into the LAA
in order to enable device delivery (fig. 1, panels B and C),
with great care to avoid injury to the thin-walled left atrial
structures [50].
After the procedure, which either requires only a short hos-
pital stay or can be an outpatient procedure, patients can re-
sume routine daily activities immediately. There are differ-
ent regimens of antithrombotic treatment after transcatheter
LAAC. While some maintain OAC for a period of several
weeks to months (recommended after implantation of the
Watchman device), others prescribe dual antiplatelet ther-
apy (recommended after the Amplatzer devices) consist-
ing of low dose acetylsalicylic acid (100 mg per day) and
clopidogrel (75 mg per day) to prevent early device-related
thrombosis until endocardialisation has covered the device
(fig. 1, panels E and F). Whereas the procedure is usually
performed using TOE guidance, it can also be done without
TOE, with fluoroscopic guidance only [50–52].
To ensure effective LAA closure and absence of device-re-
lated thrombi, TOE is usually repeated at least once 3–6
months after the procedure.
Clinical evidence for left atrial
appendage closure
A large study (LAAOS III) assessing surgical LAA closure
is currently recruiting patients [41]. Of note, in this trial,
OAC is continued after surgical LAAC in all patients, pre-
cluding any data on the efficacy of surgical LAAC without
concomitant use of OAC.
With regard to percutaneous LAAC, two randomised clin-
ical trials, one meta-analysis, and several registry studies
have been reported so far [53–58]. Table 1 summarises cur-
rent clinical trial and registry data.
Using the Watchman device, the Percutaneous Closure of
the Left Atrial Appendage Versus Warfarin Therapy for
Prevention of Stroke in Patients with Atrial Fibrillation
(PROTECT AF) trial was the first randomised, noninferi-
ority clinical trial comparing LAAC with warfarin in 707
patients with a mean CHADS2 score of 2.2 ± 1.2, who were
eligible for OAC. Warfarin was continued in addition to
acetylsalicylic acid for the first 6 weeks after implantation,
at which time a follow-up TOE was performed. The device
was successfully implanted in 88% of randomly assigned
patients and most discontinued warfarin after 6 weeks. At
1065 patient-years of follow-up, LAAC with the Watch-
man device was found noninferior to OAC for the compos-
ite primary efficacy endpoint: an endpoint event (stroke,
cardiovascular death, or systemic embolism) occurred in
3.0% per 100 patient-years in the LAAC group versus
4.9% in the OAC group with a probability of noninferi-
ority of the intervention of >99.9%. Patients treated with
the device had fewer haemorrhagic strokes (0.1 vs 1.6%,
probability of superiority of the LAAC group 99.8%). The
primary safety endpoint – a composite of major bleeding
and periprocedural complications – was more common in
the device closure group (7.7 vs 4.4% per 100 patient-
years), mainly driven by serious pericardial effusions in
4.8% of patients [53]. Of note, during long-term follow-
up (2621 patient-years) the Watchman device fulfilled cri-
teria for superiority to OAC for the primary efficacy en-
dpoint, and mortality was significantly reduced [54] (fig.
2). Subsequently, a second randomised trial, the Prospect-
ive Randomized Evaluation of the Watchman Left Atrial
Appendage Closure Device in Patients with Atrial Fibrilla-
tion Versus Long-Term Warfarin Therapy (PREVAIL) was
performed and showed improvements in procedural suc-
cess and safety [55]. Whereas the successful closure rate
increased from 88 to 95%, the rates of the coprimary en-
dpoint of cardiovascular death, stroke or systemic embol-
ism were comparable in both treatment arms at 18 months
of follow-up, although the device arm did not formally
reach noninferiority as the upper bound of the 95% cred-
ibility interval was not within the prespecified margin. In
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Table 1: Procedural success and adverse event rates of the principal left atrial appendage closure trials and registries.
Trial /
registry
studies >100
patients
n Design CHADS2
score
Mean ±
SD
Proce-
dural/
technical
success
%
Peri-
proce-
dural
death
%
Severe
peri-
cardial
effu-
sion
%
Major
device
embolis-
ation
%
Dis-
abling
stroke
%
Safety events
(periprocedural
complications)
Total
rate of
relevant/
severe
safety
events
%
Adjudi-
cation
of
events
Follow-
up:
Total
number
of
patient
years
ob-
served
Efficacy
events
Efficacy
event
rate
(per 100
patient-
years)
Duration
of
follow-
up in
months
Mean ±
SD
Remarks
PLAATO
PLAATO [73] 111 Registry 2.4 ± 1.3 97.0 0.0 0.9 0.0 Na Surgery due to
cardiac
tamponade, death
0.9 No 91.0 Stroke 2.2 9.8 Early study;
safety events
likely
underreported
PLAATO
European
Study [74]
180 Registry 3.1 ± 1.6 90.0 1.1 3.3 Na Na Stroke,
tamponade, death,
embolisation,
others
8.9 No 129.0 Stroke 2.3 9.6 ± 6.9
AMPLATZER CARDIAC PLUG and AMULET
Initial
European
registry [75]
143 Registry Na 96.0 0.0 3.5 1.4 2.1 Thromboembolism,
loss of implant in
venous system,
device embolism,
air embolism,
procedural stroke,
pericardial
tamponade
7.0 No Na Na Na Na Feasibility
study, only
procedural
safety events
reported
Iberian
Amplatzer
registry [76]
167 Registry 3.0 ± 1.0 95.0 0.0 1.2 0.6 Na Major vascular
complications,
device
embolisations,
pericardial
tamponade, TIA
5.4 No 290.0 Stroke, TIA 2.4 22.0 ±
8.3
Bern LAAC
registry [51]
152 Registry 2.7 ± 1.3 98.0 0.0 2.6 4.6 0.0 Pericardial
tamponade, device
embolisation,
stroke, major
bleeding
7.2 No Na Stroke,
systemic
embolism,
unexplained
death
2.6 32.0 Early data of
the Bern
registry
including
early results
with non-
dedicated
devices
Early safety
Israel
experience
[77]
100 Registry 3.2 ± 1.2 100.0 0.0 1.0 0.0 0.0 pericardial
tamponade,
pulmonary
oedema
1.0 No Na Na Na Na Cumulative
experience of
a single
operator
Multicentre
Amplatzer
experience
[58]
1047 Registry 2.8 ± 1.3 97.0 0.8 1.2 0.8 0.9 Death, myocardial
infarction, stroke,
TIA), systemic
embolisation, air
embolisation,
device
embolisation,
cardiac
tamponade, major
bleeding
5.0 No 1349.0 Stroke, TIA,
systemic
embolism
2.3 13.0
Bern-Zurich
LAAC
registry
(unpublished
data)
500 Registry 2.6 ± 1.3 98.0 0.4 3.0 0.6 0.2 Death, stroke,
tamponade, major
bleeding, major
access vessel
complication,
surgery, severe
kidney injury, need
for resuscitation
4.8 Yes Na Na Na Na
WATCHMAN
PROTECT-
AF trial. [53,
54, 56]
707 RCT vs
warfarin
2.2 ± 1.2 88.0 0.0 4.8 0.6 1.1 Severe pericardial
effusion, major
bleeding,
procedure- related
stroke, device
embolisation,
haemorrhagic
stroke
8.7 Yes 2621.0 Stroke,
systemic
embolism,
cardio-
vascular or
unexplained
death
2.3 46.0 ±
20.0
First
randomised
trial; proof of
concept for
LAAC with
Watchman
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PREVAIL trial
[55]
407 RCT vs
warfarin
2.6 ± 1.0 95.0 0.0 0.8 0.7 0.0 Device
embolisation,
arteriovenous
fistula, cardiac
perforation,
cardiac
tamponade, major
bleeding
4.5 Yes Na Stroke,
systemic
embolism,
unexplained
death
0.7 28.0 ±
13.0
Second
randomised
trial with
Watchman vs
warfarin
CAP [61] 460 Registry 2.4 ± 1.2 94.4 0.0 2.2 Na 0.0 Severe pericardial
effusion, major
bleeding, stroke,
device
embolisation,
haemorrhagic
stroke
4.2 Yes Na Stroke,
systemic
embolism or
cardiovascular
death
2.0 25.0 ±
10.0
ASAP [56] 150 Registry 2.8 ± 1.2 95.0 0.0 1.3 1.3 0.7 Device
embolisation,
cardiac
tamponade,
stroke,
pseudoaneurysm,
bleeding
8.7 Yes 129.0 Stroke 2.3 14.0 ±
9.0.
Study for
safety and
efficacy in
patients who
are not
eligible for
warfarin
EWOLUTION
[62]
1019 Registry 2.8 ± 1.3 98.5 0.0 0.2 0.2 0.1 Severe pericardial
effusion, major
bleeding, stroke,
device
embolisation,
haemorrhagic
stroke
2.8 Yes Na Na Na Na
LARIAT
Multicentre
registry [65]
154 Registry 2.8 ± 1.4 86.0 1.9 10.4 0.0 1.3 Death, myocardial
infarction, stroke,
bleeding, cardiac
surgery
10.4 No Na Stroke,
systemic
embolism,
cardio-
vascular or
unexplained
death
2.9 4.0
COHEREX WAVECREST
Wavecrest 1
trial. (Reddy
et al., oral.
presentation
ICI 2013)
73 Registry Na 96.0 0.0 2.0 0.0 0.0 Severe pericardial
effusion,
procedure-related
stroke, device
embolisation
0.0 No Yes Na Na 1.5
ASAP = acetylsalicylic acid plavix feasibility study with Watchman left atrial appendage closure technology; CAP = continued access protocol; CHADS2 = congestive heart failure history,
hypertension history, age >75 years, diabetes mellitus history, stroke or transient ischaemic attack symptoms previously; CV = cardiovascular; LAAC = left atrial appendage closure; Na = not
available; PREVAIL = prospective randomised evaluation of the Watchman LAA closure device in patients with atrial fibrillation vs long-term warfarin therapy; PROTECT-AF = Watchman left atrial
appendage closure system for embolic protection in patients with atrial fibrillation; pt-yrs = patient-years; RCT = randomised controlled trial; RR = risk ratio; WM = Watchman; TIA = transient
ischaemic attack
a patient-level meta-analysis of PROTECT AF, PREVAIL
and registry data, LAAC with the Watchman device as
compared with OAC was found to result in similar rates of
all-cause stroke and systemic embolism (HR 1.02, 95% CI
0.62–1.17, p = 0.94), although the lower rate of haemor-
rhagic stroke (HR 0.22, p = 0.004) was offset by the higher
rate of ischaemic stroke (HR 1.95, p = 0.05). In addition,
LAAC was associated with lower rates of cardiovascular
and unexplained death (HR 0.48, p = 0.006) and fewer non-
procedural bleeding events (HR = 0.51, p = 0.006) [57].
Quality of life has also been shown to improve in patients
who underwent LAAC compared with OAC, as well as
cost-effectiveness [59, 60].
In patients ineligible for OAC, the ASAP Study (Aspirin
Plavix Feasibility Study With Watchman Left Atrial Ap-
pendage Closure Technology) reported that LAAC with the
Watchman device can be safely performed with favour-
able results in terms of stroke prevention in the absence of
treatment with warfarin during the first 6 weeks after im-
plantation [56]. Patients were treated with dual antiplatelet
therapy for 6 months followed by acetylsalicylic acid in-
definitely and the observed rate of systemic embolism or
stroke was 2.3% per year after 14 months of follow-up (ex-
pected rate 7.3% per year).
In addition to the controlled trials, the Watchman Contin-
ued Access Protocol Registry (CAP) showed improve-
ments in device safety overcoming the initial learning
curve [61]. Furthermore, the recently published results of
the EWOLUTION registry, which included 1021 patients
with a relatively high risk for stroke and bleeding, showed
an additional reduction of major safety events to 2.8% after
7 days and to 3.6% after 30 days after LAAC with the
Watchman device [62].
Along with further improvement of implantation tech-
niques and operator skills, the net clinical benefit of LAAC
can be further increased.
As a consequence, the second generation of the Watchman
device has gained approval of the FDA in early 2015 for
stroke prevention in patients with AF as an alternative to
OAC, currently being the only FDA-approved system for
percutaneous LAAC.
Beside the Watchman device, the Amplatzer cardiac plug
and Amulet devices have been investigated in several stud-
ies, some of which were limited by retrospective design or
performance by a single operator. Most studies using the
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Amplatzer cardiac plug were performed in patients with
(relative) contraindications for OAC and hence represent a
population at higher risk for stroke and bleeding. Patients
were usually treated with acetylsalicylic acid and clopido-
grel after the procedure. Data regarding safety and effic-
acy from various studies are summarised in table 1. So far,
the largest data set regarding procedural safety and clinic-
al efficacy is derived from a multicentre registry includ-
ing 1047 patients at 20 international centres [58]. The mean
age was 75 years, the mean CHADS2 score 2.8 ± 1.3, the
mean CHA2DS2-VASc score 4.5 ± 1.6, and the HAS-BLED
score 3.1 ± 1.2. A considerable proportion of patients un-
derwent concomitant structural or coronary interventions.
Procedural success was high (>97%). The rate of peri-
procedural major adverse events (7-day rates of death,
ischaemic stroke, systemic embolism, and procedure-re-
lated or device-related complications requiring major car-
diovascular or endovascular intervention) amounted to 5%
(mortality 0.8%, cardiac tamponade 1.2%, device embol-
isation 0.1%, stroke 0.9%).
During 1349 patient-years of follow-up the rate of stroke
and systemic embolism was 2.3% in the overall population
and 1.3% in the subgroup of more than 600 patients
without concomitant coronary or structural interventions.
Compared with the expected stroke rate according to the
CHA2DS2-VASc score, a 59–77% relative risk reduction
for the efficacy endpoints of stroke and systemic embolism,
respectively, was shown. Major bleeding was reported at a
rate of 1.3% per 100 patient-years in patients with a follow-
up time longer than 1 year, and 2.1% per 100 patient-years
for the entire population. TOE investigations 3–6 months
after device implantation found a closure rate of 98% with
absence of a significant residual shunt. To date, data from
randomised trials comparing the Amplatzer Cardiac Plug
with oral anticoagulation in patients with AF are missing.
Figure 2
Primary outcomes of the Percutaneous Closure of the Left Atrial
Appendage Versus Warfarin Therapy for Prevention of Stroke in
Patients with Atrial Fibrillation (PROTECT AF) study [54]. In
comparison with warfarin, left atrial appendage closure (LAAC) with
the Watchman was superior in preventing death, stroke, and
systemic embolism. Due to periprocedural safety events, e.g.,
severe bleeding as a result of major pericardial effusion, device
embolisation and stroke, LAAC with the Watchman device was not
superior (yet not inferior either) to warfarin during a mean follow-up
time of 3.8 years with regard to safety. For the first time, LAAC has
not only shown superior results with regard to stroke prevention,
but remarkably also with regard to all cause and cardiovascular
mortality, indirectly pointing towards the hazards of oral
anticoagulation. Data reproduced from Reddy et al. [54].
A multicentre pivotal trial, comparing LAAC with Am-
platzer devices to NOAC was stopped owing to slow pa-
tient recruitment [63].
The LARIAT device has been investigated in nonrandom-
ised, small-scale observational studies. Bartus and col-
leagues reported the results of a study in 89 patients with
a success rate of 96%. The rate of serious adverse events
(pericarditis, cardiac tamponade, late strokes, unexplained
sudden cardiac death) was relatively high (10 events,
11.2%) [64]. A more recent, retrospective study of 154 pa-
tients reported a device success rate of 94%, while 10.4%
of patients experienced a relevant pericardial effusion and
9.1% of patients had major bleedings. Clinical efficacy en-
dpoints including death, myocardial infarction or stroke oc-
curred in 2.9% of patients after a median follow-up period
of 4 months. TOE revealed a relatively high rate of residual
leaks and device-related thrombi (20% and 4.8%, respect-
ively) [65].
Due to the wide variability and partly inconsistent defini-
tions of reported complications (table 1) in the various re-
gistries and trials, direct and indirect comparisons are prob-
lematic. Therefore, standardised criteria and predefined
composite endpoints, in analogy to the Bleeding Academic
Research Consortium (BARC) and Valve Academic Re-
search Consortium (VARC) criteria, are desirable. Simil-
arly, clinical outcome data have to be monitored and ad-
verse events need to be recorded and adjudicated according
to the upcoming left atrial appendage closure criteria.
Current guidelines provide a class IIb, level of evidence
B, recommendation for percutaneous LAAC [4] in patients
who are not candidates for OAC. Presumably, the role of
LAAC as a second concept in the management of AF will
grow along with development of new devices, progress-
ive skills and routine of interventional cardiologists, and of
course, with further evidence from new studies.
Safety aspects when considering left
atrial appendage closure
LAAC is a preventive treatment without immediate effect
on symptoms. Therefore, the rate of procedure-related ad-
verse events must be as low as possible. Due to the com-
plex anatomy and topography of the LAA, closure tech-
niques are more complex, technically more demanding,
and more risky than other preventive treatment strategies
such as PFO closure. PFO closure can be performed with
very low risk as attested by the absence of relevant peri-
procedural outcome differences in three randomised trials
comparing PFO closure with medical therapy [66–69]. The
event rate among AF patients undergoing LAAC is con-
siderably higher during the early period after the interven-
tion, and beneficial effects regarding prevention of haem-
orrhagic stroke and nonprocedural bleeding emerge only
during longer term follow-up [54, 57]. Regarding overall
bleeding rates, also including all procedure-related bleed-
ings, a recent analysis in 1114 patients with a median
follow-up of 3.1 years revealed noninferiority [70].
Delayed procedure-related adverse findings such as device-
related thrombi and incomplete closure with residual
shunts in the LAA are detected infrequently (fig. 4). In the
largest series of 632 patients after a median follow-up of
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7 months, thrombi were found in 4.4% and mostly treated
by reinitiation of (non-vitamin K-dependent) oral antico-
agulants. Peridevice leaks or relevant shunts were found in
1.9%, yielding a rate of complete LAA closure of 98.1%.
Of note, these findings were not linked to adverse events in
that multicentre study [58]. Also, late pericardial effusions
Figure 3
Recommended algorithm for stroke prevention in patients with atrial
fibrillation (reproduced modified from the 2014 expert consensus
statement of the European Heart Rhythm Society and the
European Association of Percutaneous Cardiovascular
Interventions [50]). The additional strategy of LAAC centres on a
risk/benefit evaluation of the optimal treatment for each patient.
Hereby, it is supposed to contribute both to improved safety and
efficacy outcomes as well as to offer protection from stroke and
death to patients who have been left without any treatment so far.
LAAC = left atrial appendage closure; NOAC = non-vitamin K-
dependent oral anticoagulant; OAC = oral anticoagulation
Figure 4
Examples of procedure-related adverse findings in the TOE follow-
up 4 months after LAAC.
The red arrow in panel A shows a device-adherent thrombus of 15
x 17 mm. After resumption of OAC, the thrombus had dissolved
without clinical sequelae after 3 months (panel B, green arrow
pointing on device surface). In panel C, the red arrow points
towards a mobile thrombus of 12 x 5 mm which adheres to the
central screw of the Amplatzer device. Also in this case, the
thrombus could be dissolved by OAC without clinical
consequences. The red arrow in panel D points at a residual shunt
of 3 mm into the LAA due to suboptimal closure.
LAA = left atrial appendage; LAAC = left atrial appendage closure;
OAC = oral antocoagulation; TOE = transoesophageal
echocardiography
with or without need for drainage and late device embolisa-
tions occured infrequently.
LAAC is a challenging intervention and both procedural
success and adverse events depend on the individual exper-
ience of the operator. The learning curve of the procedure is
shallow, which means that LAAC should be preferentially
performed at high-volume centres by experienced operators.
Patient selection and indications for
left atrial appendage closure
Prevention of stroke and systemic embolism is of para-
mount importance in patients with AF and risk factors for
stroke. OAC with a VKA or NOAC is the current standard
of care and provides excellent efficacy in terms of stroke
prevention. LAAC emerges as an additional, nonpharma-
cological treatment. The available therapeutic strategies
need to take into consideration the long-term risk of throm-
boembolism as determined with the CHA2DS2VASC score
as well as long-term bleeding risk as determined with the
HAS-BLED score. When considering LAAC, the peripro-
cedural risks need to be carefully weighed, particularly as
the intervention is performed frequently in asymptomatic
patients with primary preventive intentions, thus highlight-
ing low adverse event rates as an important prerequisite.
Other considerations include patient compliance and tol-
erance of long-term pharmacological treatment, as well as
patient preference.
Randomised clinical trials have been performed among pa-
tients who were eligible for OAC and therefore LAAC may
be considered as an alternative to OAC for patients sim-
ilar to those included in these studies. LAAC is certainly
very useful in those patients who have suffered from life-
threatening bleeding or are at high risk for bleeding and
are therefore not candidates for long-term OAC. Also, the
small group of patients who suffered from stroke despite
OAC should be considered, perhaps even for a combined
strategy. From a conceptual point of view, patients with
moderate to high risk of both stroke and bleeding may
likely benefit most from LAAC, but evidence from clin-
ical trials regarding this patient population is not avail-
able. All patients with AF who do not receive any anti-
coagulation for various reasons should be considered for
LAAC. Patients who undergo structural, electrophysiolo-
gical or coronary interventions could also benefit. Figure
3 provides a modified algorithm of the European Heart
Rhythm Society and the European Association of Percu-
taneous Cardiovascular Interventions 2014 [50].
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Figures (large format)
Figure 1
Different techniques, devices, and results for left atrial appendage closure (LAAC).
In panel A, surgical endocardial closure by exclusion with a double layer suture is depicted. Note the proximity of the left atrial appendage (LAA)
to the left pulmonary veins (LPVs) and the mitral valve (MV). Derived and modified from Robertson et al. [71] (© 2016 Beth Croce).
In panels B and C, the two most common devices for percutaneous LAAC are shown (B: derived and modified from St. Jude Medical,
Minnesota, USA; C: Image provided courtesy of Boston Scientific. © 2016 Boston Scientific Corporation or its affiliates. All rights reserved). In
contrast to the Watchman, a membrane-cap device (C), the Amplatzer systems are plug-and-disc (pacifier) devices Panel D depicts another
membrane-cap device, the Coherex Wavecrest (derived and modified from Coherex Medical, Utah, USA). In panels E and F, the Amplatzer and
Watchman devices are shown after endocardialisation in anatomical preparations of canine models (derived and modified from Kar et al. [72]
Impact of Watchman and Amplatzer devices on left atrial appendage adjacent structures and healing response in a canine model. JACC
Cardiovasc Interv. 2014;7(7):801–9, with permission from Elsevier).
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Figure 2
Primary outcomes of the Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients with
Atrial Fibrillation (PROTECT AF) study [54]. In comparison with warfarin, left atrial appendage closure (LAAC) with the Watchman was superior
in preventing death, stroke, and systemic embolism. Due to periprocedural safety events, e.g., severe bleeding as a result of major pericardial
effusion, device embolisation and stroke, LAAC with the Watchman device was not superior (yet not inferior either) to warfarin during a mean
follow-up time of 3.8 years with regard to safety. For the first time, LAAC has not only shown superior results with regard to stroke prevention,
but remarkably also with regard to all cause and cardiovascular mortality, indirectly pointing towards the hazards of oral anticoagulation. Data
reproduced from Reddy et al. [54].
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Figure 3
Recommended algorithm for stroke prevention in patients with atrial fibrillation (reproduced modified from the 2014 expert consensus statement
of the European Heart Rhythm Society and the European Association of Percutaneous Cardiovascular Interventions [50]). The additional
strategy of LAAC centres on a risk/benefit evaluation of the optimal treatment for each patient. Hereby, it is supposed to contribute both to
improved safety and efficacy outcomes as well as to offer protection from stroke and death to patients who have been left without any treatment
so far.
LAAC = left atrial appendage closure; NOAC = non-vitamin K-dependent oral anticoagulant; OAC = oral anticoagulation
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Figure 4
Examples of procedure-related adverse findings in the TOE follow-up 4 months after LAAC.
The red arrow in panel A shows a device-adherent thrombus of 15 x 17 mm. After resumption of OAC, the thrombus had dissolved without
clinical sequelae after 3 months (panel B, green arrow pointing on device surface). In panel C, the red arrow points towards a mobile thrombus
of 12 x 5 mm which adheres to the central screw of the Amplatzer device. Also in this case, the thrombus could be dissolved by OAC without
clinical consequences. The red arrow in panel D points at a residual shunt of 3 mm into the LAA due to suboptimal closure.
LAA = left atrial appendage; LAAC = left atrial appendage closure; OAC = oral antocoagulation; TOE = transoesophageal echocardiography
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